Special Issue

Small Molecules Regulating the Redox Landscape for Therapy

Message from the Guest Editor

Reactive oxygen species (ROS) play a crucial role in the regulation of physiological processes; however, deregulated ROS contribute to the development of a large number of human diseases. Consequently, the cellular redox landscape is tightly controlled by complex mechanisms that have been only partially elucidated. As of today, numerous disorders have been linked to the deregulation of ROS homeostasis, including cancer, neurodegenerative diseases and psychiatric disorders. Hence, the redox landscape is an interesting therapeutic target for the development of novel pharmaceuticals. Other strategies aim to increase ROS production to sensitize cancer cells in radiotherapy or to combat infectious agents. Often, these strategies rely on small molecules that can be classified as various. oxidants or antioxidants. Our increasing understanding of redox biology in conjunction with advances in chemical biology and medicinal chemistry enable researchers to create novel tools and compounds to modulate the redox landscape in human diseases.

Guest Editor

Dr. Dennis Özcelik

Chemistry | Biology | Pharmacy Information Center, ETH Zürich, Vladimir-Prelog-Weg 10, CH-8093 Zürich, Switzerland

Deadline for manuscript submissions

closed (15 January 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/108923

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

